Home » Our Services » Clinical Services » Research and Innovation Directorate » COVID-19 Research

COVID-19 Research

Working closely with our clinical colleagues the RBCH research team is delivering high priority COVID-19 studies. In doing so we are contributing to the national and international effort to diagnose, treat and ultimately prevent the disease. This is already having an impact on patient care and other responses to the pandemic.

For example, the RECOVERY (Randomised Evaluation of COVID-19 Therapy) trial randomly allocates patients between several treatments, given in addition to the hospital's usual standard of care. As of 13th August Bournemouth has recruited 106 patients to the trial.

'In 100 days, the RECOVERY trial has provided results enabling change in global practice three times. This extraordinary national effort has shown that two drugs used to treat hospitalised COVID patients throughout the world, hydroxychloroquine and lopinavir-ritonavir, do not improve survival, whilst one drug that was not recommended, dexamethasone, saves lives.' - Professor Peter Horby, Chief Investigator.

The team is taking part in further studies to see if existing treatments for other conditions or diseases or new drugs may be used to treat people with COVID-19. Coordinated by the National Institute of Health Research the studies have worked to integrate with each other, aiming to deliver results quickly and efficiently.

  • REMAP-CAP - a Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia. This is a critical care study running in 12 countries worldwide and created with the treat of an event such as this in mind. It uses an innovative trial design to efficiently evaluate multiple interventions simultaneously.

  • ACCORD-2 - Accelerating COVID-19 Research & Development - A platform for multiple Phase 2 studies assessing the safety of potential treatments and how well they work. Candidates are selected based on expert scientific review, with six identified so far. Those showing promise will be fed into large-scale national studies such as RECOVERY.

In addition to these 'interventional' studies we are taking part in a range of other research to improve the understanding of COVID-19 and its impacts. With so much still to learn about the disease, this range of perspectives is important to help ensure that decisions are informed by robust evidence wherever possible.

  • SIREN - Sarscov2 Immunity & REinfection EvaluatioN - A Public Health England study aiming to determine if prior SARS-CoV-2 infection protects people from re-infection. Up to 10,000 individuals who work in a clinical setting where patients are present will be studied for at least a year. Nose and throat swabs and blood samples will be taken regularly to determine new acute infections and measure their antibody response and participants will complete a questionnaire to collect information on exposure and symptoms. Within the first month Bournemouth has recruited 46 participants.

  • GENOMICC - Genetics Of Mortality In Critical Care - How susceptible we are to COVID-19 is likely to be partly down to our genes, as in other infections. Finding these genes has the potential to help prioritise treatments. This global study collects DNA samples from the critically ill patients. In partnership Genomics England, Illumina and the NHS, the study now aims to sequence the genomes of thousands of patients severely ill with coronavirus. This data, from the person’s own genome, will be linked to the virus genome data provided by the COVID-19 Genomics UK (COG-UK) Consortium.

The following observational studies collect information from the hospital records of patients admitted with COVID-19 to answer the urgent questions. In order to obtain as much information as possible, and ensure the whole patient population is represented, data is collected for all patients unless they choose to opt out.

The Trust is also taking part in these following research projects asking valuable questions about how COVID-19 affects and interacts with other conditions, and how delivery of care has been affected.

Psychological impact of the Coronavirus (COVID-19) pandemic and experience: An international survey - Researchers from a collaboration group asked people to complete a short questionnaire to help better understand how the coronavirus is affecting us all and its impact on our day to day lifestyle. They hope to find out what is helpful for people during this time and also what may be causing some people to be affected more than others in terms of their wellbeing.

The first phase of the study is now closed receiving 28,000 responses, of which Bournemouth contributed 491! We look forward to seeing the findings and participating in the next phase of the study later this year.

UK Coronavirus Monitoring Project. Patients with cancer potentially have greater susceptibility to COVID-19 and more serious complications of the disease. This could be both due to the cancer itself and treatment, with differences between different cancer types. Doctors and patients are having to make difficult decisions regarding their condition including whether or not to treat and if so what treatment and how it is given. It is important that these are informed by the best available evidence. UKCCMP aims 'to collect identify and learn from every case of COVID-19' and provide 'live' updates.

COVER Study - COvid-19 Vascular sERvice Study - The COVER study is a three-tiered project aiming to understand and evaluate the evolving impact of the COVID-19 pandemic on vascular surgery service provision, condition management and the effect on outcomes for those patients presenting and managed during the pandemic.